Skip to main content
MorphoSys AG logo

MorphoSys AG — Investor Relations & Filings

Ticker · MOR ISIN · DE000A3H2XW6 LEI · 529900493806K77LRE72 F Manufacturing
Open in API
Filings indexed 1,418 across all filing types
Latest filing 2021-10-18 Declaration of Voting R…
Country DE Germany
Listing F MOR

About MorphoSys AG

https://www.morphosys.com/

MorphoSys AG is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines, primarily for cancer patients. The company specializes in creating therapeutic monoclonal antibodies, utilizing its long-standing expertise and proprietary technology platforms to generate fully human antibodies. Its research and development efforts are concentrated on building a pipeline of novel treatments to address significant unmet medical needs in oncology. In February 2024, Novartis entered into an agreement to acquire MorphoSys, aiming to integrate its antibody technologies and oncology pipeline.

Recent filings

Filing Released Lang Actions
Declaration of Voting Results & Voting Rights Announcements 2021
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled 'Voting Rights Announcements' and explicitly states 'Notification of Major Holdings' under German Securities Trading Act (WpHG) regulations. It details the acquisition/disposal of shares and instruments, showing the resulting percentage of voting rights held by The Goldman Sachs Group, Inc. This type of filing, which reports changes in significant share ownership thresholds, directly corresponds to the definition of Major Shareholding Notification (MRQ). Although it mentions 'Voting Rights Announcements' in the header, the content is a detailed disclosure of holding changes, which is the core function of an MRQ filing.
2021-10-18 English
Declaration of Voting Results & Voting Rights Announcements 2021
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is explicitly titled 'Voting Rights Announcements' and contains detailed tables reporting changes in share ownership, specifically focusing on 'Notification of Major Holdings' under German Securities Trading Act (WpHG) regulations. Section 6 details the 'Total positions' of voting rights before and after the change, and Section 5 specifies the date the threshold was crossed (11 Oct 2021). This content directly matches the definition of a notification regarding changes in significant share ownership levels, which corresponds to the Major Shareholding Notification category (MRQ). Although it is a regulatory announcement disseminated via DGAP, the specific nature of the content (major holding change) overrides the general 'RNS' fallback.
2021-10-18 English
Declaration of Voting Results & Voting Rights Announcements 2021
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is explicitly titled 'Voting Rights Announcements' and contains detailed tables reporting changes in voting rights percentages held by JPMorgan Chase & Co. in MorphoSys AG, referencing specific sections of the German Securities Trading Act (WpHG, specifically Article 40 and Sec. 33, 34, 38). This content directly corresponds to the definition of reporting personal share transactions or changes in significant ownership thresholds by major shareholders/insiders, which aligns best with the 'Director's Dealing' (DIRS) or 'Major Shareholding Notification' (MRQ) categories. Since this filing specifically details the acquisition/disposal of shares with voting rights and reports the total positions crossing thresholds by a major entity (JPMorgan Chase & Co.), it is a notification of a change in significant share ownership. The category 'Major Shareholding Notification' (MRQ) is the most precise fit for reporting changes in ownership thresholds by large investors, even if the filer is not a director.
2021-10-13 English
MorphoSys' Licensing Partner Roche Received Breakthrough Therapy Designation for Gantenerumab in Alzheimer's Disease
Regulatory Filings Classification · 1% confidence The document is titled 'News Details' and is dated October 11, 2021. It announces that MorphoSys's licensing partner, Roche, received Breakthrough Therapy Designation from the FDA for Gantenerumab. The text uses terms like 'Media Release', 'DGAP-News', and discusses clinical trial progress and licensing agreements. This is a general corporate announcement regarding a significant development (FDA designation) that is not a formal financial report (like 10-K or IR), a specific shareholder vote result (DVA), or a management change (MANG). Since it is a news release about a corporate event/development, and it doesn't fit the specific categories like ER (Earnings Release) or CAP (Financing Update), it falls best under the general 'Regulatory Filings' (RNS) category, which serves as a broad category for miscellaneous regulatory/corporate news announcements distributed via services like DGAP.
2021-10-11 English
DGAP-DD: MorphoSys AG english
Director's Dealing Classification · 1% confidence The document explicitly contains the header "Directors’ Dealings" and the title "DGAP-DD: MorphoSys AG english". It details a transaction (Acquisition) by a "person discharging managerial responsibilities" (Member of the managing body) regarding the issuer's shares. This directly corresponds to the definition of Director's Dealing, which is classified as code DIRS.
2021-10-04 English
Declaration of Voting Results & Voting Rights Announcements 2021
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is explicitly titled 'Voting Rights Announcements' and contains detailed tables reporting changes in voting rights percentages and the total number of voting rights held by a major shareholder (The Goldman Sachs Group, Inc.) in MorphoSys AG, referencing specific sections of the German Securities Trading Act (WpHG). This directly corresponds to the definition of a Major Shareholding Notification, which tracks changes in significant ownership thresholds. Although the header mentions 'Voting Rights Announcements', the content structure aligns perfectly with the 'Major Shareholding Notification' (MRQ) category, which covers changes in significant share ownership levels crossing thresholds.
2021-10-04 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.